xAI Sues Man for Allegedly Using Grok to Generate AI Child Abuse Deepfakes 
SpaceX Stock Falls Below IPO Price as Investors Weigh Losses and Lockup Expiry 
Apple Intelligence Cleared for China as Alibaba and Baidu AI Power iPhone Features 
Taiwan Mangoes Head to Europe as Premium Fruit Exports Expand 
BHP Faces Major Port Hedland Strike as Labor Talks Stall Ahead of Production Report 
DeepSeek Eyes China IPO as AI Startup Seeks $71 Billion Valuation in New Funding Round 
Sodexo Unveils Shift & Grow 2030 Strategy, Targets Over 5% Revenue Growth by Fiscal 2030 
BHP Q4 Iron Ore Output Rebounds as Copper Prices Boost Revenue 
Stripe, Advent Offer $53 Billion Deal to Acquire PayPal: Reuters 
SK Hynix Stock Soars as AI Memory Demand Outlook Fuels Chip Rally 
Alibaba Stock Jumps as China Approves Apple Intelligence Powered by Qwen AI 
Arm Stock Falls After HSBC Downgrade, Citing Limited Near-Term AI Upside 
DBS Targets S$1 Trillion Wealth AUM by 2030 Amid Asia Wealth Boom 
Apple Intelligence China Approval Lifts Alibaba and Baidu Shares 
UBS Boosts China Tech Bets, Adds Kuaishou and Meituan to Focus List 
Hyundai Takes Full Control of Boston Dynamics to Accelerate Humanoid Robot and AI Strategy 
Jamie Dimon Warns Anthropic's Mythos AI Poses National Security Risks 
SOUTH SAN FRANCISCO, Calif., Jan. 27, 2016 -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a biopharmaceutical company focused on developing meaningful therapies for patients with unmet medical needs in diseases that have seen limited therapeutic innovation, today announced its participation in two upcoming investor conferences:
- Canaccord Genuity Rare Disease, BioPharma 1x1 Day
Tuesday, February 2, 2016
Omni Berkshire Place Hotel, New York, NY
- SunTrust Robinson Humphrey 2016 Orphan Drug Day
Tuesday, February 23, 2016
JW Marriott Essex House, New York, NY
About Atara Biotherapeutics, Inc.
Atara Biotherapeutics, Inc. is a biopharmaceutical company developing meaningful therapies for patients with unmet medical needs in diseases that have seen limited therapeutic innovation, with an initial focus on immunotherapy and oncology. Atara Bio’s programs include T-cell product candidates and molecularly targeted product candidates. The T-cell product candidates include EBV-CTL, CMV-CTL and WT1-CTL and harness the power of the immune system to recognize and attack cancer cells and cells infected with certain viruses. The molecularly targeted product candidates include STM 434. These product candidates target activin and myostatin, members of the TGF-beta family of proteins, and have demonstrated the potential to have therapeutic benefit in a number of clinical indications.
INVESTOR & MEDIA CONTACT: Investors: Steve Klass 212-213-0006 x331 [email protected] Media: Justin Jackson 212-213-0006 x327 [email protected]
